Xenon Pharmaceuticals XENE Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0-100% | $7.5M0.0% | $7.5M0.0% | $7.5M0.0% | $7.5M— | ||
| $328.25M+9.1% | $300.94M+10.4% | $272.71M+8.0% | $252.63M+11.1% | $227.34M+8.1% | ||
| $84.41M+6.0% | $79.63M+5.4% | $75.57M+3.5% | $72.99M-0.2% | $73.15M+6.2% | ||
| $412.66M+8.4% | $380.57M+9.3% | $348.28M+7.0% | $325.62M+8.4% | $300.5M+7.6% | ||
| -$412.66M-10.6% | -$373.07M-9.5% | -$340.78M-7.1% | -$318.12M-8.6% | -$293M-4.9% | ||
| $27.51M-2.4% | $28.18M-9.3% | $31.08M-12.5% | $35.53M-5.2% | $37.48M-8.3% | ||
| -$385.15M-11.7% | -$344.89M-11.4% | -$309.7M-9.6% | -$282.6M-10.6% | -$255.52M-7.2% | ||
| -$1.98M-295% | $1.02M+130% | -$3.37M+22.8% | -$4.37M-7.2% | -$4.07M+0.4% | ||
| -$383.17M-10.8% | -$345.91M-12.9% | -$306.33M-10.1% | -$278.23M-10.7% | -$251.45M-7.3% | ||
| -$4.70-7.8% | -$4.36-12.1% | -$3.89-9.6% | -$3.55-9.9% | -$3.23-7.0% | ||
| -$410.19M-10.7% | -$370.53M-9.6% | -$338.18M-7.2% | -$315.5M-8.7% | -$290.36M-4.9% | ||
| -$412.66M-10.6% | -$373.07M-9.5% | -$340.78M-7.1% | -$318.12M-8.6% | -$293M-4.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Xenon Pharmaceuticals's income statement data come from?
- Every line is extracted from Xenon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.